PROVENGE® (sipuleucel-T) is an autologous cellular
immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic
castrate-resistant (hormone-refractory) prostate cancer.
IMPORTANT SAFETY INFORMATION
Acute Infusion Reactions: Acute infusion reactions
(reported within 1 day of infusion) may occur and include nausea, vomiting, fatigue, fever,
rigor or chills, respiratory events (dyspnea, hypoxia, and bronchospasm), syncope, hypotension,
hypertension, and tachycardia.
Thromboembolic Events: Thromboembolic events,
including deep venous thrombosis and pulmonary embolism, can occur following infusion of
PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had
multiple risk factors for these events. PROVENGE should be used with caution in patients with
risk factors for thromboembolic events.
Vascular Disorders: Cerebrovascular events
(hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders
(myocardial infarctions) have been reported following infusion of PROVENGE. The clinical
significance and causal relationship are uncertain. Most patients had multiple risk factors for
Handling Precautions: PROVENGE is not tested for
transmissible infectious diseases.
Concomitant Chemotherapy or Immunosuppressive Therapy:
Chemotherapy or immunosuppressive agents (such as systemic corticosteroids) given
concurrently with the leukapheresis procedure or
PROVENGE has not been studied. Concurrent use of immune-suppressive
agents may alter the efficacy and/or safety of PROVENGE.
Adverse Reactions: The most common adverse reactions
reported in clinical trials (≥ 15% of patients receiving PROVENGE) were chills, fatigue,
fever, back pain, nausea, joint ache, and headache.
to see more.